Skip to main content
Premium Trial:

Request an Annual Quote

Cellecta Human and Mouse Genome-Wide CRISPRa and CRISPRi Libraries and Mouse CRISPR Knockout Library

Cellecta added CRISPRa and CRISPRi genome-wide, human and mouse pooled screening libraries to its portfolio of CRISPR products and services. Cellecta also supplemented its current portfolio of CRISPR gene knockout libraries by adding a Mouse Genome-Wide CRISPR Knockout Library. These new additions to Cellecta's CRISPR portfolio enable researchers to study enhanced gene activation or gene inhibition without modifying genomic DNA, the company said. The gene-regulating CRISPRa and CRISPRi variations make use of an altered CRISPR protein to enhance or inhibit gene expression, rather than inducing mutational changes in a gene's coding sequence. Access to these new libraries provide researchers with new tools to identify potential drug targets or biomarkers, and elucidate mechanisms of drug action.

Key features of the new Cellecta CRISPRa and CRISPRi libraries include single-module format, with each library expressing some 106,000 sgRNAs (human) and 109,000 sgRNAs (mouse) averaging five sgRNAs per gene promoter region; CRISPRa and CRISPRi libraries targeting approximately 19,000 human genes and almost 20,000 mouse genes; and approximately 4,000 non-targeting sgRNA controls.

The new CRISPR Mouse Genome-Wide Knockout Library, based on the canonical CRISPR/Cas9 system, extends knockout screening capability to mouse model systems. The Cellecta CRISPR mouse knockout library targets all mouse protein-coding genes and features approximately 80,000 constructs comprise the single-module library, four sgRNAs target functional domains and conserved transcript regions in each of 19,600 mouse genes, and complete panel of controls include standard, non-targeting controls.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.